SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial

Authors :: Markus Borner
Ralph Winterhalder
U Hasler-Strub
Daniel Rauch
Marc Küng
Thomas Ruhstaller
Sandro Anchisi
Martin Bigler
Juerg Bernhard
Christoph Rochlitz
Richard Cathomas
Kyung Jae Na
Daniela Baertschi
Roger von Moos
Andreas Mueller
Tamara Rordorf
Marcus Vetter
Khalil Zaman
Andreas Trojan
Source :: Journal of Clinical Oncology. 32:518-518
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 518 Background: Bevacizumab combined with chemotherapy has been shown to improve response rate and PFS in metastatic breast cancer. The aim of our study was to demonstrate decreased toxicity of met...

Tools